Profile
Joanne Schindler's former job positions include Vice President-Clinical Development at Constellation Pharmaceuticals, Inc., Chief Medical Officer at IMV, Inc., Vice President-Clinical Development at H3 Biomedicine, Inc., and Executive VP, Head-Medical & Clinical Development at Fusion Pharmaceuticals, Inc. She has also received an undergraduate degree from Brandeis University and a doctorate degree from The University of Connecticut School of Medicine.
Former positions of Joanne Schindler
| Companies | Position | End |
|---|---|---|
| IMV INC. | Chief Tech/Sci/R&D Officer | 11/06/2021 |
| FUSN PHAR | Chief Tech/Sci/R&D Officer | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Chief Tech/Sci/R&D Officer | - |
Training of Joanne Schindler
| Brandeis University | Undergraduate Degree |
| The University of Connecticut School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IMV INC. | Health Technology |
| FUSN PHAR | Health Technology |
| Private companies | 2 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- Joanne Schindler
